lncRNA NONRATT013819.2 promotes transforming growth factor-β1-induced myofibroblastic transition of hepatic stellate cells by miR24-3p/lox

Abstract Long noncoding RNAs (lncRNAs) are key regulators of hepatic stellate cells (HSCs), yet the role of upregulated lncRNA-NONRATT013819.2 in activated HSCs remains uncertain. In this study, the effects of NONRATT013819.2 on proliferation, apoptosis, migration, and contraction of transforming growth factor (TGF)-β1-induced HSCs were investigated. The mechanisms of NONRATT013819.2 on the activated HSCs were explored by loss-of-function of NONRATT013819.2 and gain-of-function of the target gene. Here, TGF-β1 treatment resulted in a gradual increase in the expression of cytoskeleton markers (collagen, α-SMA, and TIMP1), NONRATT013819.2, miR24-3p, and lysyl oxidase (Lox) over time in HSCs. NONRATT013819.2 acted as a sponge of miR24-3p to competitively abolish the inhibition of the lox gene in HSCs. Silencing of NONRATT013819.2 suppressed the expression of cytoskeleton markers, proliferation, and the proportion of cells that entered the S-phase, and promoted apoptosis in TGF-β1-activated HSCs. These effects were reversed when lox overexpression was introduced simultaneously. Similarly, silencing of NONRATT013819.2 also blocked ECM reconstruction, while recused by lox overexpression in TGF-β1-activated HSCs. In conclusion, upregulation of NONRATT013819.2 promotes the myofibroblastic transition by competitively binding miR24-3p to release lox in HSCs. Therefore, targeted therapy of NONRATT013819.2 may have the potential for liver fibrosis.


Introduction
Hepatic stellate cells (HSCs), which are located in the Disse gap between the hepatocyte plate and hepatic sinus, play an important role in the pathogenesis of liver fibrosis [1]. In normal liver, quiescent HSCs have weak relaxation and contraction. However, when there is liver damage, HSCs transition from a quiescent state to an activated state and the activated HSCs acquire the migratory, proliferative, and myofibroblast-like phenotype [2]. This myofibroblastic transition process leads to the accumulation of myofibroblasts, which contributes to the formation of liver fibrosis and the reconstruction of intrahepatic structures by secreting extracellular matrix (ECM) [3]. However, the mechanisms of HSC phenotypic transformation remain poorly understood.
Long noncoding RNAs (lncRNAs) are a novel class of ncRNAs with transcripts containing more than 200 nucleotides [4]. Current studies indicate that lncRNAs serve as activators or suppressors of HSCs to participate in the occurrence and development of myofibroblastic transition. For instance, lncRNA NEAT1-induced autophagy and activation of HSCs in mice [5]. To explore the differential expression profile of lncRNA during HSC myofibroblastic transition, we previously performed high-throughput sequencing in primary quiescent and activated HSC of rats. We found that the expression level of lncRNA NON-RATT013819.2 was significantly upregulated more than fivefold in activated HSCs compared to the quiescent HSCs [6]. Meanwhile, the expression of NONRATT013819.2 was positively correlated with that of the lysyl oxidase (lox) gene, which is adjacent to each other at the chromosomal location [6]. However, whether NONRATT013819.2 and lox are involved in HSC myofibroblastic transition and the possible underlying mechanism remains unclear.
It is well known that miRNAs initiate the degradation of mRNA by binding to miRNA response elements (MREs) of mRNA with the attendant inhibition of the translation of target genes [7]. Numerous studies have found that the same MREs also exist on lncRNA and circRNA. Hence, different types of RNA containing MREs can "communicate" with one another simply by competing for the shared miRNAs, acting as ceRNAs, through the formation of lncRNA-miRNA-mRNA or circRNA-miRNA-mRNA ceRNA regulation networks [8]. This hypothesis is widely adopted when studying the role of lncRNA in disease pathogenesis. However, whether the relationship between NONRATT013819.2 and lox depends on ceRNA remains unclear.
In this study, we performed an overall analysis of the effects of NONRATT013819.2 on the biological properties of HSCs and investigated its mechanism. Our findings may improve the understanding of the myofibroblastic transition of HSCs and provide a novel therapeutic strategy against the activation and progression of liver fibrosis.
2 Materials and methods 2.1 Isolation, culture, and treatment of rat HSCs Primary HSCs were isolated from three normal male Sprague-Dawley rats (weighing 400-500 g) by in situ perfusion and density gradient centrifugation using a modification of the methodology previously described by Friedman et al. [9]. Briefly, animals were anesthetized with ether and treated with 0.1 cc heparin sodium (1 mL/kg) via direct inferior vena cava injection immediately before perfusion. Subsequently, the serial infusion was carried out via rodent portal vein using D-Hank's solution and then perfusion medium (Hank's medium with 0.5 g/L collagenase IV and 1 g/L pronase E). Afterward, the isolated rat liver was cut into pieces and exposed to re-digestion using collagenase IV and DNase. Finally, the rat HSCs were isolated from cell suspension by density gradient centrifugation using 180 g/L Nycodenz (Sigma-Aldrich, St. Louis, MO, USA). Activation of HSCs was induced by the transforming growth factor (TGF)-β1 at a concentration of 10 ng/mL, and the cells were cultured for 0, 12

Construction of vectors
The following steps were involved in the construction of a silencing vector of lncRNA NONRATT013819.2. First, we designed a specific siRNA sequence that complementarily binds to NONRATT013819.2. Then, a complementary shRNA-DNA sequence with a hairpin structure was obtained according to the siRNA sequence. Next, the shRNA-DNA sequences were cloned into the linear pSIH1-H1-copGFP shRNA vector (System Biosciences, Palo Alto, CA, USA) to obtain lncRNA NONRATT013819.2 silencing vector (tagged as pSIH1-shRNA-NONR). Meanwhile, an invalid siRNA sequence was used as a negative control (NC) and tagged as pSIH1-NC. Finally, DNA sequencing was used to confirm the constructed vectors (pSIH1-shRNA-NONR and pSIH1-NC). All the primers are shown in Table S1. Construction of the overexpression vector of lox. The coding sequence of rat lox (NM_017061.2, 1808 bp) was amplified using PCR, which contained an EcoRI cutting site, Kozak sequence (5′-GCCACC-3′], and a BamHI cutting site. The product of PCR amplification was digested and cloned into a pcDH1-GFP lentiviral expression vector (System Biosciences). The recombinant vector was tagged pcDH1-lox and confirmed by DNA sequencing. Empty vectors were used as controls. All the primers are listed in Table S1.

Lentivirus packaging and infection
Transfection was carried out when the cells were in the logarithmic growth phase. Here, 2 µg recombinant vector (pSIH1-shRNA-NONR, pSIH1-NC, and pcDH1-lox) and 10 µg of pPACK™ Packaging Plasmid Mix (System Biosciences) were co-transfected into cells using diluted Lipofectamine 2000 (2 µL was diluted with 50 µL OPTI-MEM; Invitrogen, Carlsbad, CA, USA). After a 48-h culture, the supernatant was harvested and cleared by centrifugation at 5,000×g at 4°C for 5 min and then filtered by a 0.45 µm polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). The titer of the virus was determined by gradient dilution. Furthermore, the established lentiviruses with the sequences of shRNA-NONR, lox, and NC were tagged Lv-shRNA-NONR, Lv-lox, and Lv-NC, respectively.
Thereafter, HSCs cell line of lncRNA NONRATT013819.2 silencing and Lox overexpression were produced by lentiviral infection using the aforementioned packaged lentiviruses of Lv-shRNA-NONR and Lv-lox, respectively. The lentiviral infection was conducted when HSCs were in the logarithmic growth phase on six-well plates at 5 × 10 5 cells/well. The viral solution was added at a multiplicity of infection (MOI) of 10. Infection efficiency was assessed by GFP fluorescence after infection for 72 h by a fluorescence inverted microscope (IX71, Olympus, Japan).

Analysis of RT-qPCR
Total RNA was isolated using the TRIzol ® Reagent (Invitrogen; Thermo Fisher Scientific). RT-qPCR was performed in triplicate for each sample. The relative amounts of NONRATT013819.2 and Lox were normalized against β-actin and miR24-3p against U6 snRNA. The fold change for each gene was calculated by the 2 −ΔΔCt method. The primers used are shown in Table S1.

Luciferase activity assay
The current study utilized Targetscan7.1 (http://www. targetscan.org/) to predict the binding site of miR24-3p on the 3′ untranslated region (UTR) of Lox mRNA, and the binding sites of miR24-3p on NONRATT013819.2. Primers that targeted the 3′ UTR of the lox gene were designed such that flanking XbaI restriction sites were introduced into the 228-bp PCR product containing the miR24-3p target site (5′-TGAGCC-3′]. The primer sequences of PCR are shown in Table S1. PCR product was digested with XbaI (Takara Bio) and cloned into the pGL3-promoter luciferase reporter vector (Promega, Madison, WI, USA) to generate the vector pGL3-wild type (wt)-Lox. The miR24-3p target site in the pGL3-wt-Lox vector was mutated from 5′-TGAGCC-3′ to 5′-GCGCTA-3′ to construct the mutated reporter vector, tagged as pGL3-mt-Lox, using a Site-Directed Mutagenesis Kit (Takara Bio). The products of the vectors were confirmed by DNA sequencing. Endotoxinfree DNA samples were prepared in all cases. The miR24-3p mimic, the miR24-3p inhibitor, and miR24-3p NC were all synthesized by Invitrogen (Thermo Fisher Scientific) and then co-transfected with pGL3-wt-Lox or pGL3-mt-Lox into 293 cells. The sequences are shown in Table S1. Luciferase activity was measured using the dual-luciferase reporter assay system (Promega) after transfection for 48 h. Moreover, the effect of NONRATT013819.2 depletion on the luciferase activity of miR24-3p mimics was also observed in activated HSCs.

Cell Counting kit-8 assay
The HSCs viability was examined using Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan). After viral infection of HSCs for 48 h, HSCs were induced by 10 ng/mL TGF-β1 for 72 h, and then, the cells were harvested for the assay. Each sample was set with six repeating wells. The HSCs were seeded in a 96-well plate at a density of 2 × 10 3 cells/well and cultured for 24 h. Then, 10 µL of CCK-8 reagent 8 was added to each well and cultured for another 12, 24, 48, and 72 h. Absorbance was measured at 450 nm on a microplate reader (Molecular Devices, Tokyo, Japan).

Flow cytometry
The cell cycle distributions and apoptosis rates of HSCs were measured by flow cytometry on fluorescence-activated cell sorting (FACS) Calibur (BD Biosciences, Franklin Lakes, NJ, USA) as previously described [10]. After viral infection of HSCs for 48 h, HSCs were induced by 10 ng/mL TGF-β1 for 72 h, and then, the cells were harvested for assay. Freshly isolated HSCs were fixed and then stained with propidium iodide followed by FACS analysis.

Gel contracture experiment
After viral infection of HSCs for 48 h, HSCs were induced by 10 ng/mL TGF-β1 for 72 h, and then, the cells were harvested for contraction assay on collagen gel. Rat-tail collagen (4 g/L; BD Biosciences) was preplated in 12-well plates and cultured for 1 h at 37°C to allow for gelatinization. Next, HSCs were plated on top of the gel (the density of cells and volume of gel were 1 × 10 6 cells/well and 50 μL, respectively) and co-cultured for 48 h. Experiments were terminated by adding 53% ethanol. Finally, gels were imaged, and the collagen gel contraction was observed based on the area of the gels.

Immunofluorescence staining
The α-SMA expression of HSCs was evaluated by immunofluorescence (IF) staining. HSCs were harvested and washed with phosphate-buffered solution and then fixed in 4% paraformaldehyde. Next, HSCs were permeabilized with 0.5% Triton X-100 and blocked by 5% bovine serum albumin. Then, HSCs were incubated with monoclonal antibodies specific for α-SMA (1:100; Sigma-Aldrich, St. Louis, MO, USA) at 4°C for overnight followed by incubation with the secondary antibody. Finally, HSCs were observed under confocal laser scanning microscopy.

Cell invasion experiments
The cell invasion experiments were performed using the QCMTM 24-well Fluorimetric Cell Invasion Assay kit (ECM554, Chemicon International, USA) according to the manufacturer's instructions using the Transwell system. The invading cells were stained with 4′,6-diamidino-2-phenylindole, and their number was determined by fluorescence and reported as the relative fluorescence units.

Statistical analysis
All the results are expressed as mean ± standard deviation (SD). Statistical analysis was performed using an independent Student's t-test for comparison of two groups and one-way ANOVA following Tukey's test for multiple comparisons. In both cases, differences of P < 0.05 were considered statistically significant.

Activation of HSCs in vitro
To obtain activated HSCs, 10 ng/mL TGF-β1 was used to induce HSCs and changes in the indicators at different time points were observed. After induction by 10 ng/mL TGF-β1 for 72 h, the expression of fibroblast activation markers (collagen I, α-SMA, and TIMP1) in HSCs were detected by western blotting. As a result, the protein expression of collagen I, α-SMA, and TIMP1 increased with induction time (Figure 1a-d). The protein expression of collagen I and α-SMA peaked at 72 h followed by a decrease at 96 h (Figure 1a, b, and d). TIMP1 protein expression peaked at 96 h, but there was no difference from 72 h (Figure 1c and d). These results showed that 10 ng/mL TGF-β1 induction for 72 h is the optimal induction condition for HSC activation. Thus, these induction conditions were used for further studies.
3.2 lncRNA NONRATT013819.2, miR24-3p, and lox expressions were upregulated in activated HSCs Next, we detected the expression of NONRATT013819.2 in activated HSCs. RT-qPCR showed that the NONRATT013819.2 expression was increased over time and peaked at 96 h ( Figure 1e). This increase in activated HSCs is consistent with RNA sequencing data in our previous study [6]. Since we previously revealed a positive correlation between the expression levels of NONRATT013819.2 and lox, we detected the expression of lox. Interestingly, we found that the mRNA expression of lox had no obvious change in the activated HSCs (Figure 1f), but the protein expression was completely consistent with the changing trend of NONRATT013819.2 (Figure 1d and g). This prompted us to speculate that ceRNA interactions contain NONRATT013819.2 and lox. By utilizing Targetscan7.1 (http://www.targetscan.org/), we predicted a unique miRNA that could target both NONRATT013819.2 and lox, namely, miR24-3p (Figure 1h). The results showed that the expression of miR24-3p was also increased over time and peaked at 72 h ( Figure 1i). Therefore, NONRATT013819.2, miR24-3p, and lox expressions were upregulated in activated HSCs. This unusual phenomenon allows us to continue exploring the relationships among them in activated HSC.
3.3 NONRATT013819.2 weakened the suppression effect of miR24-3p on lox in a ceRNA manner Examination of the homology between miR24-3p and lox mRNA sequences showed that the six-base seed region 5′-GUAGCC-3′ is in the 3′ UTR according to the online software TargetScan (http://www.targetscan.org) (Figure 2a). Thus, an inhibitory effect of miR24-3p was inferred. Dualluciferase assay showed that luciferase activity in the HSCs of miR24-3p mimics and miR24-3p inhibitor co-transfected with pGL3-wt-Lox was significantly lower or higher than that of pGL3-wt-Lox alone transfected group, respectively ( Figure 2b). As expected, this effect could be abolished by a partial mutation in the 3′ UTR of lox mRNA (pGL3-mt-Lox group) (Figure 2b). These results confirmed the direct interaction between miR24-3p and lox.
Importantly, these results suggested that silencing of NONRATT013819.2 exacerbated the suppressive effects of miR24-3p on lox. In addition, according to the results, silencing of NONRATT013819.2 may be responsible for the inhibitory effects of miR24-3p on lox.

Lentiviral pathway-mediated silence of NONRATT013819.2 and lox overexpression
To explore the function of NONRATT013819.2 and lox on HSCs, we constructed the lentiviruses of NONRATT013819.2 silence, lox overexpression, and control. Next, the packaged lentiviruses were tagged Lv-shRNA-NONR, Lv-lox, and Lv-NC. The proportion of cells with GFP expression was not less than 90%, indicating that the efficiency of lentiviral infection was sufficient for further studies (Figure 3a). Compared with blank HSCs (HSC) and Lv-NC group, NON-RATT013819.2 expression was significantly downregulated in the Lv-shRNA-NONR group, suggesting that the silencing efficiency was high (Figure 3b). Western blot showed that protein expression of Lox in the Lv-shRNA-NONR group was significantly decreased compared to blank HSCs group or Lv-NC group, but it was significantly upregulated in the Lv-lox group, indicating the high efficiency (Figure 3c).

Silencing NONRATT013819.2 inhibited biological function in TGF-β1-activated HSCs by miR24-3p/Lox
Further, we assessed changes in the biological functions after silencing NONRATT013819.2 or overexpressing Lox in TGF-β1-activated HSCs. We found that TGF-β1 induction significantly increased the proliferation of HSCs (Figure 4a) and the proportion of cells that entered the S-phase ( Figure 4b) and inhibited apoptosis in HSCs (Figure 4c). However, silencing NONRATT013819.2 reversed the aforementioned effects ( Figure 4). These results suggested that silencing NON-RATT013819.2 blocked the activation effects of TGF-β1 on HSCs. Moreover, TGF-β1-induced HSCs activation being dependent on NONRATT013819.2 was confirmed at the molecular level. As shown in Figure 5a, silencing NON-RATT013819.2 inhibited the TGF-β1-induced increase in protein expressions of collagen I, α-SMA, and TIMP1. Thus, TGF-β1-induced myofibroblast transition of HSCs is in a NONRATT013819.2-dependent manner. Subsequently, we investigated the mechanism of NONRATT013819.2-dependent myofibroblast transition of HSCs. We found that compared with NONRATT013819.2 silencing group, overexpression of Lox prominently reversed the inhibitory effects of NONRATT013819.2 silencing on In TGF-β1-activated HSCs, the effect of silencing NONRATT013819.2 on the interaction of miR24-3p with lox was detected by dual-luciferase assay. The relative activity of luciferase in each group was detected at 48 h after co-transfection. The results were expressed as the mean ± SD from three independent experiments, *P < 0.05, **P < 0.01.  The cell cycle of HSCs was detected by flow cytometry after silencing of NONRATT013819.2 or overexpression lox. Y-axis represents cell number. X-axis represents the DNA content dictated by the channel of FL2-A. Dp stands for Diploid. Both G1 and G2 are annotated in red, this is because the annotation of G1 and G2 is automatically defined by FACS Calibur without the confusion of cells in each phase. The * indicates comparison with group HSC; the # indicates comparison with group HSC + Lv-shRNA-NONR + TGF-β1. (c) The apoptosis HSCs was detected by flow cytometry after silencing NONRATT013819.2 or overexpression lox. The lower and upper right quadrants indicated the proportion of apoptotic cells in the early and late stages, respectively. The apoptosis rate between groups was the sum of the early and late apoptosis rates. The results were expressed as the mean ± SD from three independent experiments, # and *P < 0.05, **P < 0.01. protein expressions of collagen I, α-SMA, and TIMP1 (Figure 5a). These suggest that Lox is involved in the NONRATT013819.2associated regulatory activation of HSCs. As shown in Figure 5b, silencing NONRATT013819.2 resulted in a decline in the expressions of NONRATT013819.2 and lox, whereas overexpression of lox significantly restored the expression of Lox in TGF-β1-induced HSCs. However, we observed that neither deletion of NONRATT013819.2 nor overexpression of lox altered the expression of miR24-3p (Figure 5b). This is consistent with the aforementioned results. Therefore, we hypothesized that this might be because NONRATT013819.2 only competitively binds to miR24-3p in a miRNA-sponge manner to weaken the inhibitory ability of miR24-3p to the target gene, lox, but NONRATT013819.2 does not degrade miR24-3p.

Silencing NONRATT013819.2 inhibited ECM reconstruction through Lox
As mentioned previously, silencing NONRATT013819.2 and overexpression of lox affected the protein expressions of collagen I, α-SMA, and TIMP1, which play an important role in ECM reconstruction. Therefore, we then verify whether NONRATT013819.2 could change ECM reconstruction through Lox in TGF-β1-induced HSCs. The gel contraction results showed that the diameter of gels was significantly reduced in the TGF-β1-induced group, but significantly dilated after NONRATT013819.2 silencing, suggesting that silencing NONRATT013819.2 suppressed surface tension of HSCs (Figure 6a). In contrast, overexpression of lox exaggerated gel contraction characterized by the obviously concave surface of the gels (Figure 6a). Moreover, rescue experiments showed that silencing NONRATT013819.2 while overexpressing lox partially abolished gel changes caused by treatment alone (Figure 6a). Similarly, the invasion of HSCs was significantly enhanced by TGF-β1, while silencing NON-RATT013819.2 inhibited this enhancement, which also could be restored by overexpression of lox (Figure 6b). We also detected the protein expression of α-SMA in HSCs using IF. As shown in Figure 6c, silencing NONRATT013819.2 suppressed the increased trend in α-SMA protein expression in HSCs induced by TGF-β1, which was reversed by overexpression of lox. Taken together, silencing NONRATT013819.2 inhibited ECM reconstruction of HSCs induced by TGF-β1 through regulating lox.  HSCs go through myofibroblast transdifferentiation to acquire a migratory, myofibroblast-like phenotype is the key step in liver fibrosis. This is a multifactorial process involving excessive proliferation, apoptotic resistance, dysregulated metabolism, and remodeling of ECM [11]. All these fibrosis-inducing pathophysiological disorders demonstrate an intimate association with abnormality in various kinds of ncRNAs (e.g., miRNA, lncRNA, and circRNA) [12].
Dramatically, differential expression of lncRNAs (e.g., ATB, MALAT1, LFAR1, AS1, p21, SCARNA10, and NON-RATT013819.2) usually precedes the change in the ncRNA network, which further contributes to the progression of liver fibrogenesis [6,[13][14][15]. Among them, NONRATT013819.2 has been reported to have significant upregulation during HSC-to-myofibroblast transdifferentiation [6]. In this study, we proved that silencing of NONRATT013819.2 could block myofibroblastic transition of HSCs, characterized by inhibition of proliferation; the proportion of HSCs that entered S-phase; protein expressions of collagen I, α-SMA, and TIMP1; and the promotion of apoptosis, through miR24-3p/lox axis. In our study, on the basis of bioinformatics predictions and the results of dual-luciferase assays, we were convinced that NONRATT013819.2 interacted with miR24-3p via base complementary pairing to further regulate the lox expression in a ceRNA mechanism. CeRNA means that it can competitively abolish the inhibitory effects of miRNA on a target gene and then regulates the expression of the target gene. Therefore, in the present study, the silencing of NONRATT013819.2 was uncovered to be responsible for the inactivation of miR24-3p function on lox. Unusually, expressions of NONRATT013819.2, miR24-3p, and lox were upregulated in the TGF-β1-induced HSCs. Also, either silencing NONRATT013819.2 or overexpression of lox could not alter miR24-3p expression. The reason may lie in the fact that the sequestering of miR24-3p by NONRATT013819.2 inevitably reduces the interactions between the miR24-3p and lox, which may affect the levels of free miR24-3p instead of its overall content in HSCs due to NONRATT013819.2 only sponges, but does not affect the synthesis and degradation of miR24-3p.
Growing evidence indicates that ECM composition is a critical determinant of multiple phenotypes of HSCs (i.e., proliferation, apoptosis, migration, and contraction), which are largely based on interactions between collagen and cell adhesion molecules [16]. For instance, the pathophysiological disorder of contraction of hydrated collagen gel underlies portal hypertension during the progression of liver fibrosis/cirrhosis [17]. Furthermore, an interaction of ECM (including collagens I/III, fibronectin, α-SMA, etc.) and myofibroblasts has been proved to exert important effects on the phenotypes and functions of myofibroblasts [18]. Myofibroblasts with activated phenotype induced the excessive deposition and altered the composition of ECM, which further promoted the fibrosis-inducing characteristics of myofibroblasts [18]. Therefore, in our study, increased protein expressions of collagen I, α-SMA, and TIMP1, and gel contraction were considered to be a feature of myofibroblastic transition of the HSCs.
Recently, Lox and Lox-like (LoxL) isoforms 1-3 have been shown to be involved in liver fibrosis [19]. In Cav-1 −/− or periostin −/− mice with CCl 4 exposure, the hepatic expression of Lox is upregulated with the exacerbation of fibrosis [19][20][21]. In contrast, administration of Lox inhibitor, β-aminopropionitrile, suppressed the accumulation of cross-linked collagens and the stiffness of collagen fibril in the ECM, accelerating fibrosis reversal after CCl 4 withdrawal [22,23]. Mechanistically, activation of Lox family proteins (i.e., Lox and LoxLs) mediates the deoxypyridinoline and pyridinoline crosslinks in collagen, and the increase in collagen crosslinking promotes its stabilization and contributes to the irreversibility of fibrosis [24,25]. In addition, Lox and LoxLs are responsible for the tropoelastin crosslinking and polymerization of elastin that forms fibrosis-related elastic fibers [26]. Therefore, Lox promotes liver fibrosis and prevents spontaneous reversal via collagen. This conclusion is supported by our results. In the present study, overexpression of Lox synergistically promoted the activation of TGF-β1 on HSCs, characterized by increased protein expressions of collagen I, α-SMA, and TIMP1, and these effects were reversed by silencing NONRATT013819.2. Consequently, the promoting role of NONRATT013819.2 in the myofibroblastic transition of HSCs is mediated by Lox/collagen.
Numerous studies have shown that miR24-3p is involved in a wide range of human diseases, including those associated with abnormal collagen synthesis. The miR24-3p has been demonstrated to be significantly upregulated in HCVpositive hepatocellular carcinoma as compared to the control [27]. Yang et al. proved that overexpression of miR24-3p regulated collagen synthesis and skin barrier [28]. In addition, overexpression of miR24-3p elevated the protein expression of collagen type II to weaken cartilage degradation induced by IL-1β [29]. In this study, a significant increase in collagen I was observed to be accompanied by abnormal upregulation of miR24-3p, suggesting an association between them. Based on the aforementioned ceRNA theory, we concluded that NONRATT013819.2 and miR24-3p competitively binding to lox is the possible mechanism of collagen I responding to TGF-β1 induction.
In conclusion, TGF-β1-induced activation of HSCs resulted in expression of NONRATT013819.2 and lox was upregulated, and proteins of myofibroblast markers also accumulated, which may contribute to increased proliferation, apoptosis resistance, migration, and contraction of activated HSCs. NONRATT013819.2 exerts the aforementioned effects by eliminating the inhibition of lox expression by miR24-3p. Thus, NONRATT013819.2/miR24-3p/Lox signaling is a novel pathway involved in the myofibroblastic transition of HSCs, and we proposed a possible NONRATT013819.2-targeting strategy for the management of myofibroblastic transition and even the treatment of liver fibrosis.